PlainPharmaWatch

CMS Open Payments · Tool

Genesis Software Innovations, LLC vs Astellas Pharma Europe Ltd

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Genesis Software Innovations, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,538, versus 1,263 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Genesis Software Innovations, LLC
HHI 1,538 · top recipient 0.3%
Ranked #852 of 1,838 companies by HHI
Astellas Pharma Europe Ltd
HHI 1,263 · top recipient 0.3%
Ranked #928 of 1,838 companies by HHI

Payment Overview

Total Payments
$520.5K
% of Industry
0.0%
Transactions
16
Avg per Transaction
$32.5K
Recipients
8
Avg per Recipient
$65.1K
Payment Types
1
Top Payment Type
Royalty or License
Total Payments
$523.2K
% of Industry
0.0%
Transactions
167
Avg per Transaction
$3.1K
Recipients
167
Avg per Recipient
$3.1K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Genesis Software Innovations, LLC vs Astellas Pharma Europe Ltd - total reported payments in CMS Open Payments PY2024

Astellas Pharma Europe Ltd$523.2KGenesis Software Innovation…$520.5K

Payment Types Breakdown

Genesis Software Innovations, LLC

Royalty or License $10.8K

2.1%

Astellas Pharma Europe Ltd

Consulting Fee $287.7K

55.0%

Travel and Lodging $222.5K

42.5%

Compensation for Services Other Than Consulting $11.4K

2.2%

Food and Beverage $1.6K

0.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Genesis Software Innovations, LLC

  1. 1

    Robert Sean Churchill

    $2,792.10 · 1 txns

  2. 2

    Christopher Keith Jones

    $1,974.90 · 1 txns

  3. 3

    John Itamura

    $1,253.04 · 1 txns

  4. 4

    Kyle McClintock

    $1,116.84 · 1 txns

  5. 5

    Michael Purnell

    $1,021.50 · 1 txns

Astellas Pharma Europe Ltd

  1. 1

    STEPHEN FREEDLAND

    $151,538.63 · 27 txns

  2. 2

    TERENCE FRIEDLANDER

    $45,633.38 · 10 txns

  3. 3

    PETER O DONNELL

    $41,977.00 · 5 txns

  4. 4

    STEVEN GOLDSTEIN

    $38,338.79 · 22 txns

  5. 5

    VADIM S KOSHKIN

    $33,606.52 · 17 txns

Summary Comparison

Metric Genesis Software Innovations, LLC Astellas Pharma Europe Ltd
Total Payments $520.5K $523.2K
% of Industry Total 0.0% 0.0%
Transaction Count 16 167
Avg per Transaction $32.5K $3.1K
Recipient Count 8 167
Avg per Recipient $65.1K $3.1K
Payment Type Count 1 4
Top Payment Type Royalty or License Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.